Literature DB >> 23014067

New and old knowledge on differentiated thyroid cancer epidemiology and risk factors.

L Agate1, L Lorusso, R Elisei.   

Abstract

Differentiated thyroid cancer (DTC) represents 1-2% of all human malignancies. The annual incidence varies among countries and it is estimated that 1.2-2.6 men and 2.0-3.8 women/100,000 individuals are affected worldwide. This incidence has been increasing in the last decades, likely due to an "over-diagnosis" of small cancers that would have remained occult and that have been likely revealed because of an increased diagnostic scrutiny rather than a real increase of incidence. The annual mortality rate for DTC is 0.5/100,000 both in men and women. DTC is 2-4 times more frequent in females than in males. The mean age at diagnosis is 40-45 yr for papillary tumors (PTC) and 50-55 yr for follicular tumors (FTC). They are very rare in children. Ninety percent of DTC are represented by PTC hystotype, mainly follicular and classical variants. In the last years it has been observed an important change in the oncogenic pattern of PTC with a significant reduction of RET/PTC rearrangements and an increase of BRAFV600E mutation suggesting a change in pathogenic events. The unique well-demonstrated risk factor of DTC is the exposure to external radiation which is also correlated with the presence of RET/PTC rearrangements. Recently, other environmental factors (i.e. living in a volcanic area or in a iodine- either deficient or rich area) or some eating habits leading to obesity have been considered as potential DTC risk factors. However, at present, the favorite hypothesis is that a complex interaction between genetic and environmental factors is required to develop DTC.

Entities:  

Mesh:

Year:  2012        PMID: 23014067

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report.

Authors:  Li Jin Duo; Jiang Rong; Wang Bin; Ma Chun Hua; Sun Li Wei; L V Yuan
Journal:  Oncol Lett       Date:  2015-05-04       Impact factor: 2.967

2.  Common genetic variant on 14q13.3 contributes to thyroid cancer susceptibility: evidence based on 12 studies.

Authors:  JiaoJiao Zheng; Chen Li; Cong Wang; Zhilong Ai
Journal:  Mol Genet Genomics       Date:  2015-01-01       Impact factor: 3.291

3.  TITF1 and TITF2 loci variants indicate significant associations with thyroid cancer.

Authors:  Peiliang Geng; Juanjuan Ou; Jianjun Li; Yunmei Liao; Ning Wang; Ganfeng Xie; Rina Sa; Chen Liu; Lisha Xiang; Houjie Liang
Journal:  Endocrine       Date:  2015-07-25       Impact factor: 3.633

4.  BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency.

Authors:  P Agretti; F Niccolai; T Rago; G De Marco; A Molinaro; M Scutari; C Di Cosmo; G Di Coscio; M Vitale; M Maccheroni; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2014-09-07       Impact factor: 4.256

5.  Common genetic variants on FOXE1 contributes to thyroid cancer susceptibility: evidence based on 16 studies.

Authors:  Yixin Zhuang; Weixin Wu; Han Liu; Weixin Shen
Journal:  Tumour Biol       Date:  2014-04-18

Review 6.  The role of surgery in the current management of differentiated thyroid cancer.

Authors:  Giovanni Conzo; Nicola Avenia; Giuseppe Bellastella; Giancarlo Candela; Annamaria de Bellis; Katherine Esposito; Daniela Pasquali; Andrea Polistena; Luigi Santini; Antonio Agostino Sinisi
Journal:  Endocrine       Date:  2014-04-10       Impact factor: 3.633

Review 7.  Occupation and thyroid cancer.

Authors:  Briseis Aschebrook-Kilfoy; Mary H Ward; Curt T Della Valle; Melissa C Friesen
Journal:  Occup Environ Med       Date:  2014-03-06       Impact factor: 4.402

8.  FOXE1 association with differentiated thyroid cancer and its progression.

Authors:  Marissa Penna-Martinez; Friederike Epp; Heinrich Kahles; Elizabeth Ramos-Lopez; Nora Hinsch; Martin-Leo Hansmann; Ivan Selkinski; Frank Grünwald; Katharina Holzer; Wolf O Bechstein; Stefan Zeuzem; Christian Vorländer; Klaus Badenhoop
Journal:  Thyroid       Date:  2014-01-29       Impact factor: 6.568

9.  Evaluating the Time Interval for Presenting the Signs of Hypocalcaemia after Thyroidectomy.

Authors:  Mostafa Hosseini; Hamidreza Alizadeh Otaghvar; Adnan Tizmaghz; Ghazaal Shabestanipour; Parichehr Atef Vahid
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 10.  Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses.

Authors:  Y Fang; Y Ding; Q Guo; J Xing; Y Long; Z Zong
Journal:  J Endocrinol Invest       Date:  2013-05-30       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.